Novavax Inc (NASDAQ:NVAX) shares traded -1.99% down during most recent session to reach at the closing price of $1.48. The stock exchanged hands 7.12 Million shares versus average trading capacity of 6.38 Million shares, yielding a market cap of $418.32 Million. Wall Street analysts covering the stock are projecting that the stock will reach $1.78 within the next 52-weeks. The mean target projections are based on 5 opinions.
Taking a broader look brokerage firms’ analysts on the street with an expectant view have Novavax Inc (NASDAQ:NVAX) high price target of $3 and with a conservative view have low price target of $0.9.
Cantor Fitzgerald “Initiates Coverage On” Novavax Inc (NASDAQ:NVAX) in a research note issued to investors on 12/16/16 to Neutral with price target of $2.
Additionally on 9/20/16 Chardan Capital “Maintained” Novavax Inc (NASDAQ:NVAX) to Neutral setting price target at $1.5 and on 9/19/16 Citigroup “Maintained” the stock to Neutral at $1.5. Furthermore on 9/16/16 PiperJaffray “Downgrades” the stock to Neutral at $1.
On the other hand the company has Relative Strength Index (RSI 14) of 73.12 along with Average True Range (ATR 14) of 0.09, Consequently Novavax Inc (NASDAQ:NVAX)’s weekly and monthly volatility is 14.18%, 7.44% respectively. The company’s beta value is at 1.96.
In terms of Buy, Sell or Hold recommendations, Novavax Inc (NASDAQ:NVAX) has analysts’ mean recommendation of 2.7. This is according to a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.
According to analysts Novavax Inc (NASDAQ:NVAX)’s minimum EPS for the current quarter is at $-0.17 and can go high up to $-0.15. The consensus mean EPS for the current quarter is at $-0.16 derived from a total of 6 estimates from the analysts who have weighed in on projected earnings. However the company reported $-0.29 earnings per share for the same quarter during last year.
Previously Novavax Inc (NASDAQ:NVAX) reported $-0.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $-0.17 by $0.01. The company posted an earnings surprise of 5.9%.
Novavax Inc (NASDAQ:NVAX)’s revenue estimates for the current quarter are $6.02 Million according to 5 number of analysts, for the current quarter the company has high revenue estimates of $6.6 Million in contradiction of low revenue estimates of $5.5 Million. For the current year the company’s revenue estimates are $25.2 Million compared to low analyst estimates of $22 Million and high estimates of $29.2 Million according to 5 number of analysts.
Currently Novavax Inc (NASDAQ:NVAX)’s shares owned by insiders are 0.5%, whereas shares owned by institutional owners are 49.9%. However the six-month change in the insider ownership was recorded 17.94%, as well as three-month change in the institutional ownership was recorded 0.09%.
Novavax Inc (NASDAQ:NVAX) 52-week high price stands at $8.49 and low price stands at $0.73, its price distance from 52-week high is -82.57% while its distance from 52-week low price is 102.74%. The stock hit its 52-week high on 09/15/16, and 52-week low on 05/08/17.
Novavax Inc (NASDAQ:NVAX)’s trailing twelve month revenues are $16.8 Million, whereas its price to sales ratio for the same period is 24.9. Its book value per share for the most recent quarter is $-0.11 while its price to book ratio for the same period is 0, as for as the company’s cash per share for the most recent quarter is $0.75, however its price to cash per share ratio for the same period is 1.98. The stock has 5 year expected PEG ratio of 0 whereas its trailing twelve month P/E ratio is 0.